Met Positive Control
| Code | Size | Price |
|---|
| MBL-CY-E1080 | 100 Assays | £421.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
Dry Ice
Storage:
-70°C
Documents
Further Information
Applications:
Other - 1
unit/well
Background:
The MET receptor tyrosine kinase was discovered because of the ability of Met to mediate chemically-induced transformation of a human osteogenic sarcoma cell line. The ligand of the Met receptor is HGF/scatter factor, known to stimulate invasive growth of epithelial cells. Signaling pathways activated by the HGF-Met interaction mediate cell adhesion and motility. In addition, Met is involved in malignant cell transformation. Increased Met expression has been found in a significant percentage of human cancers and is amplified during the transition between primary tumors and metastasis. Dysregulation of Met activity in cells is thought to be a key event underlying tumor metastasis, and indeed, Met over-expression and hyperactivation are reported to correlate with metastatic ability of the tumor cells.
Gene IDs:
Human: 4233 Mouse: 17295
MW:
Met Positive Control demonstrates a single 59 kDa band by
SDS-PAGE analysis.
Purity:
>75% pure as determined by SDS-PAGE analysis.
Shelf Life:
1 year
Target:
Met
References
1. Cooper, C.S., et al. Nature. 311:29?33, 1984
2. Bottaro, D.P., et al. Science. 251:802?804, 1991.
3. Schmidt, L., et al. Nat. Genet. 16:68?73, 1997.
4. Schmidt, L., et al. Oncogene. 18:2343?2350, 1999.
5. Olivero, M., et al. Int. J. Cancer.82:640?643, 1999.
6. Park, W.S., et al. Cancer Res. 59:307?310, 1999.
7. Lee, J.H., et al. Oncogene. 19:4947?4953, 2000.
8. Di Renzo, M.F., et al. Oncogene. 19:1547?1555, 2000.
9. Comoglio, P.M., and Trusolino, L. J. Clin. Invest. 109:857?
862, 2002.
10. Christensen JG, et al. Cancer Res. 63(21):7345-55, 2003.
11. Sattler M, et al. Cancer Res. 63(17):5462-9, 2003.